Merck and Moderna report Phase 3 melanoma vaccine data
FROM THE WIRE · FINANCE.YAHOO.COM
Merck and Moderna reported Phase 3 data from the INTerpath-001 trial in resected high-risk melanoma, where personalized mRNA therapy intismeran autogene plus KEYTRUDA reduced the risk of recurrence or death by 42% and distant metastasis or death by 38% compared with KEYTRUDA…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive Phase 3 data could open a new oncology revenue stream for Moderna, though production is complex.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The INTerpath-001 trial covers resected high-risk melanoma.
- 02Intismeran autogene plus KEYTRUDA reduced recurrence or death risk by 42% versus KEYTRUDA alone.
- 03The one-patient-at-a-time manufacturing model implies complex and costly production.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Moderna, Inc.221.72 USDMarket closedtoday -0.47%Positive Merck & Co., Inc.149.52 USDMarket closedtoday +2.18%Positive
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets